Bupivacaine transdermal - DURECT
Alternative Names: DUR-843; ELADUR; IPX-239; TRANSDUR®-BupivacaineLatest Information Update: 19 Dec 2021
At a glance
- Originator DURECT Corporation; EpiCept Corporation
- Developer DURECT Corporation
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Postherpetic neuralgia
- Discontinued Back pain
Most Recent Events
- 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
- 21 Dec 2015 Phase-II development for Postherpetic neuralgia is ongoing in USA
- 31 Aug 2015 Phase-II development for Postherpetic neuralgia is ongoing in USA